Free Trial

eXoZymes (EXOZ) Competitors

eXoZymes logo
$10.00 -0.18 (-1.77%)
As of 07/8/2025 04:00 PM Eastern

EXOZ vs. AURA, ATXS, DBVT, AVIR, ANNX, AVTE, RCKT, GLUE, OLMA, and AARD

Should you be buying eXoZymes stock or one of its competitors? The main competitors of eXoZymes include Aura Biosciences (AURA), Astria Therapeutics (ATXS), DBV Technologies (DBVT), Atea Pharmaceuticals (AVIR), Annexon (ANNX), Aerovate Therapeutics (AVTE), Rocket Pharmaceuticals (RCKT), Monte Rosa Therapeutics (GLUE), Olema Pharmaceuticals (OLMA), and Aardvark Therapeutics (AARD). These companies are all part of the "pharmaceutical products" industry.

eXoZymes vs. Its Competitors

eXoZymes (NASDAQ:EXOZ) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

In the previous week, eXoZymes had 4 more articles in the media than Aura Biosciences. MarketBeat recorded 4 mentions for eXoZymes and 0 mentions for Aura Biosciences. eXoZymes' average media sentiment score of 1.37 beat Aura Biosciences' score of 0.00 indicating that eXoZymes is being referred to more favorably in the media.

Company Overall Sentiment
eXoZymes Positive
Aura Biosciences Neutral

eXoZymes has higher revenue and earnings than Aura Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eXoZymes$70K1,195.71-$5.86MN/AN/A
Aura BiosciencesN/AN/A-$86.92M-$1.90-3.29

eXoZymes' return on equity of 0.00% beat Aura Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
eXoZymesN/A N/A N/A
Aura Biosciences N/A -58.63%-49.74%

96.8% of Aura Biosciences shares are owned by institutional investors. 72.4% of eXoZymes shares are owned by insiders. Comparatively, 5.4% of Aura Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aura Biosciences has a consensus price target of $22.00, suggesting a potential upside of 252.00%. Given Aura Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Aura Biosciences is more favorable than eXoZymes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
eXoZymes
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aura Biosciences
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.25

Summary

eXoZymes beats Aura Biosciences on 7 of the 12 factors compared between the two stocks.

Get eXoZymes News Delivered to You Automatically

Sign up to receive the latest news and ratings for EXOZ and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXOZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EXOZ vs. The Competition

MetriceXoZymesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$85.21M$2.87B$5.47B$8.95B
Dividend YieldN/A2.46%5.25%4.04%
P/E RatioN/A20.8026.9620.11
Price / Sales1,195.71286.27430.20119.79
Price / CashN/A41.1936.8257.86
Price / Book8.007.487.985.56
Net Income-$5.86M-$55.04M$3.16B$248.40M
7 Day Performance-1.96%2.44%2.39%4.67%
1 Month Performance-28.37%1.90%2.18%6.64%
1 Year PerformanceN/A4.35%33.82%21.31%

eXoZymes Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EXOZ
eXoZymes
N/A$10.00
-1.8%
N/AN/A$85.21M$70K0.0029
AURA
Aura Biosciences
1.874 of 5 stars
$6.59
+2.0%
$22.00
+233.8%
-14.6%$331.28MN/A-3.4750Positive News
ATXS
Astria Therapeutics
1.7941 of 5 stars
$5.81
+1.4%
$30.00
+416.4%
-31.4%$327.86MN/A-3.1130
DBVT
DBV Technologies
3.5978 of 5 stars
$11.54
+12.0%
$14.75
+27.8%
+163.8%$316.05M$4.15M-2.3580
AVIR
Atea Pharmaceuticals
2.3203 of 5 stars
$3.67
+1.1%
$6.00
+63.5%
+11.3%$314.08MN/A-2.2270Positive News
ANNX
Annexon
2.6579 of 5 stars
$2.86
+1.6%
$12.50
+337.8%
-43.3%$313.23MN/A-2.4260News Coverage
Positive News
AVTE
Aerovate Therapeutics
N/A$10.80
-0.4%
N/A-82.8%$313.04MN/A-3.6120High Trading Volume
RCKT
Rocket Pharmaceuticals
4.8795 of 5 stars
$2.93
+1.7%
$18.60
+534.8%
-85.7%$312.90MN/A-1.11240Trending News
GLUE
Monte Rosa Therapeutics
1.3291 of 5 stars
$5.05
+6.7%
$15.33
+203.9%
+30.1%$310.38M$75.62M63.0890
OLMA
Olema Pharmaceuticals
1.7128 of 5 stars
$4.43
-2.5%
$24.50
+453.5%
-58.0%$302.83MN/A-2.2070Positive News
AARD
Aardvark Therapeutics
N/A$13.92
+3.0%
$33.00
+137.1%
N/A$302.06MN/A0.0018

Related Companies and Tools


This page (NASDAQ:EXOZ) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners